Immune checkpoint therapy based on either anti-CTLA-4 or anti-PD-1/PD-L1 blocking antibodies inactivates the brakes on T cells, allowing broad activation of T cells, including tumor-specific T cells. This evidence concerns the gene PDCD1 and neoplasm.